Organic compounds

Fire-Resistant Cable Market by Insulation Material, End-use Industry and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Technology, Hardware, Other Manufacturing, Manufacturing, Organic polymers, Plastics, Organic compounds, Polyolefins, Building materials, Commodity chemicals, Dielectrics, Thermoplastics, Cross-linked polyethylene, High-density polyethylene, Electrical wiring, Building insulation materials

The "Fire-Resistant Cable Market by Insulation Material (EPR, LSZH, PVC, XLPE), End-use Industry (Automotive & Transportation, Building & Construction, Energy, Manufacturing), and Region (North America, Europe, APAC, MEA, South America) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fire-Resistant Cable Market by Insulation Material (EPR, LSZH, PVC, XLPE), End-use Industry (Automotive & Transportation, Building & Construction, Energy, Manufacturing), and Region (North America, Europe, APAC, MEA, South America) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global fire-resistant cable market size is projected to grow from USD 1.8 billion in 2021 to USD 2.1 billion by 2026, at a Compound Annual Growth Rate (CAGR) of 3.3%.
  • The global fire-resistant cable market has witnessed high growth primarily because of the booming construction as well as industrial sector, rise in the demand for fire safety products, and rapid urbanization & globalization.
  • In terms of both value and volume, the APAC fire-resistant cable market is projected to grow at the highest CAGR during the forecast period.

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, August 4, 2021
Organic compounds, Chemical compounds, Chemistry, G1 Therapeutics, Trilaciclib

Operating expenses for the second quarter of 2021 were $44.8 million, compared to $33.0 million for the second quarter of 2020.

Key Points: 
  • Operating expenses for the second quarter of 2021 were $44.8 million, compared to $33.0 million for the second quarter of 2020.
  • Cost of goods sold expense for the second quarter of 2021 were $0.8 million, compared to $0 for second quarter of 2020.
  • ET today to provide a corporate and financial update for the second quarter 2021 ended June 30, 2021.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

Entasis Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Chemical compounds, Moraxellaceae, Organic compounds, Medical specialties, Bacterial diseases, Antibiotics, Acinetobacter, Multidrug-resistant Gram-negative bacteria, Zoliflodacin, Sulbactam

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.

Key Points: 
  • WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush PacGrow Healthcare Conference, to be held virtually from August 10-11, 2021.
  • Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).
  • For more information, visit www.entasistx.com .

G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

Retrieved on: 
Wednesday, August 4, 2021
Organic compounds, Chemical compounds, Chemistry, Medical terminology, Healthcare reform in the United States, Diagnosis-related group, G1 Therapeutics, Trilaciclib, Medicare, G1, Garbage-first collector

An NTAP provides additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount.

Key Points: 
  • An NTAP provides additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount.
  • As such, beginning on October 1, 2021, CMS will provide an additional maximum payment of$5,526.30for COSELA when used in the inpatient hospital setting for fiscal year 2022.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemical compounds, Health sciences, Organic compounds, Orphan drugs, Breakthrough therapy, Aziridines, Cancer treatments, Mitomycin C, Oncology, Fast track, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/

Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference

Retrieved on: 
Tuesday, August 3, 2021
Genuity, Psilocybin, Psychoactive drugs, Organic compounds, Chemistry

San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.

Key Points: 
  • San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.
  • The conference will be held virtually on August 10-12, 2021.
  • Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN) program for chronic pain and eating disorder indications.
  • Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience.

Infinite Reaffirms Its Status As A Premium Brand With New Website, Featuring A Sleek Look And Seamless User Experience

Retrieved on: 
Tuesday, August 3, 2021
Organic polymers, Materials, Organic compounds, Fused filament fabrication, Thermoplastics, Plastics, 3D printing, Open-source hardware, 3D printing filament, Filament, Polyether ether ketone, Polyethylene terephthalate

It recently launchedAquaSys120 and AquaSys180, water-soluble support filament that pair with popular build materials ranging from PLA to PEEK to support complex designs.

Key Points: 
  • It recently launchedAquaSys120 and AquaSys180, water-soluble support filament that pair with popular build materials ranging from PLA to PEEK to support complex designs.
  • This spring, it launched Caverna PP, a 3D printing filament that allows users to create lightweight foam parts resembling a sponge.
  • Infinite now seeks to showcase another one of its unique assets deep industry and application knowledge.
  • All of this content is featured through a highly-focused user experience that makes content easy to find, navigate, and digest.

Infinite Reaffirms Its Status As A Premium Brand With New Website, Featuring A Sleek Look And Seamless User Experience

Retrieved on: 
Tuesday, August 3, 2021
Organic polymers, Materials, Organic compounds, Fused filament fabrication, Thermoplastics, Plastics, 3D printing, Open-source hardware, 3D printing filament, Filament, Polyether ether ketone, Polyethylene terephthalate

It recently launchedAquaSys120 and AquaSys180, water-soluble support filament that pair with popular build materials ranging from PLA to PEEK to support complex designs.

Key Points: 
  • It recently launchedAquaSys120 and AquaSys180, water-soluble support filament that pair with popular build materials ranging from PLA to PEEK to support complex designs.
  • This spring, it launched Caverna PP, a 3D printing filament that allows users to create lightweight foam parts resembling a sponge.
  • Infinite now seeks to showcase another one of its unique assets deep industry and application knowledge.
  • All of this content is featured through a highly-focused user experience that makes content easy to find, navigate, and digest.

ESPERION Reports Second Quarter 2021 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 3, 2021
Esperion Therapeutics, Pfizer, Health care, Bempedoic acid, Clinical medicine, Ezetimibe, Organic compounds

ANN ARBOR, Mich., Aug. 03, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.

Key Points: 
  • Prescriptions Grew 28% During the Quarter; More Than 47,800 Patients Have Filled a Prescription for NEXLETOL (bempedoic acid) Tablets or NEXLIZET (bempedoic acid and ezetimibe) Tablets
    ANN ARBOR, Mich., Aug. 03, 2021 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ:ESPR), the lipid management company, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
  • Royalty revenue for the second quarter 2021 was $1.0 million and $1.6 million for the six months ended June 30, 2021.
  • Total revenue for the second quarter ended June 30, 2021 was $40.7 million and $48.6 million for the six months ended June 30, 2021, compared to $212.2 million and $214.1 million for the comparable periods in 2020.
  • ESPERION will host a conference call and webcast today, August 3, 2021 at 8:00 A.M. Eastern Time to provide a second quarter 2021 financial results and company update.

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

Retrieved on: 
Monday, August 2, 2021
Organic compounds, Chemical compounds, G1 Therapeutics, Chemistry, Trilaciclib

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the appointment of Andrew Perry as its Chief Commercial Officer (CCO).
  • As we continue to evolve as a commercial company and execute on the launch of COSELA (trilaciclib), we are excited to announce the addition of Andrew to the G1 Therapeutics Executive Team, said Jack Bailey, Chief Executive Officer of G1 Therapeutics.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.